[Debut] Tupai Medical completed 200 million yuan D round of financing, Tsinghua independent technology continues to lead the innovation of ophthalmic equipment

[First Release] Tupai Medical has completed a 200 million yuan D-round financing, and Tsinghua's independent technology continues to lead innovation in ophthalmic equipment

Article reprint on Automatic Pulse Network

Recently, Tupai Medical, a leading enterprise in high-end ophthalmic medical equipment in China, completed a 200 million yuan D-round financing. This round of financing was led by Jingwei Venture Capital and followed by institutions such as Gaotejia Investment.

Tupai Medical was founded in 2017, with its core technology derived from the transformation of Tsinghua University's technological achievements. The core technology team is composed of dozens of Tsinghua faculty, students, and alumni. Since its establishment, the company has achieved breakthroughs in multiple categories of high-end ophthalmic equipment through vertical integration of ophthalmic clinical needs, innovative system functions, and high-performance upstream devices.

Layout four major product lines,
Realize independent technological breakthroughs

At present, Tupai has completed the layout of four major product lines: OCT, microscope, ultra wide angle camera, and biometric instrument. Its ongoing projects such as super emulsion glass cutting and femtosecond laser have also made key progress

• In November 2020, Tupai's first heavyweight product, the "Beiming Kun" ophthalmic OCT product, was unveiled at the Xiamen National Ophthalmology Annual Conference (CCOS2020), achieving the world's fastest scanning speed of 400000 times and pioneering fast ultra wide angle OCTA blood flow imaging detection, and promoting its inclusion in the glycemic network diagnostic guidelines.

• In March 2021, the Tupai "Ziwu" optical biometric instrument product, with its "panoramic dynamic eye axis imaging" function, opened a new era of biometric technology.

• In December 2022, at the Retina China 2022 conference in Changsha, Tupai released the prototype of the "Fubei" intraoperative OCT navigation surgical microscope, marking Tupai's entry into the high-end market in this most important equipment segment of ophthalmology.

• In September 2023, Tupai unveiled the "Biyun" digital holographic OCT navigation surgical microscope prototype at the Changsha National Ophthalmology Annual Conference (CCOS2023), achieving a comprehensive layout in the high-end market of surgical microscopes.

  
  

• In April 2024, Tupai held a launch event for the "Candle Illumination" ultra wide angle fundus camera, further improving its layout in the field of high-end ophthalmic examination equipment.

  
  

• In June 2024, at the Retina China 2024 conference in Wuxi, two high-end surgical microscope products, Tupai's "Clearing Clouds" and "Brushing Snow", were launched and released. In accordance with the standard Wet Lab, numerous renowned ophthalmic experts conducted animal eye surgeries on-site, experiencing the "science fiction level" new surgical mode of navigation in digital holography, and gave unanimous praise. They praised the major equipment field of domestic high-end ophthalmic surgical microscopes, which finally achieved independent technological breakthroughs.

Figure: Wuxi Fundus Disease Association, "Dial cloud" digital holographic intraoperative navigation microscope launched, the expert experience

Image: Tupai Medical Ophthalmic Equipment Full Series
Leverage scientific research resources,
Accelerate the comprehensive localization of ophthalmic medical equipment

Since its establishment, Tupai Medical has been based on the domestic optoelectronic industry and research institution resources, focusing on independent research and development of key optoelectronic devices. When the functionality of the product system is limited by devices, the company can still achieve performance breakthroughs in the vertical direction through underlying technology. This mode has also driven the technical progress in the medical direction in the field of optoelectronic devices in China, reflecting the direct promotion of new quality productivity on medical equipment enterprises.

According to the Blue Book on the Status and Future Development Trends of the High end Ophthalmic Equipment Industry released by Frost Sullivan, in 2023, the market share of Tupai Medical's OCT products in public hospitals has reached 27%, ranking first in the domestic market and the first Chinese enterprise to achieve a "full product line" layout of high-end ophthalmic medical equipment.

Fortunately, with the promotion of excellent domestic enterprises such as Tupai Medical, the trust of Chinese ophthalmologists in domestic products has greatly increased. I believe that in the future, with the launch of the high-end surgical microscope products such as "Tupai" and "Fu Xue" series, as well as the promotion of new products such as "Candle Illumination" and "Zi Wu", the comprehensive localization of ophthalmic medical equipment will be rapidly achieved.

In addition, Tupai Medical products have achieved sales and installation in many countries such as France, Italy, Switzerland, the Netherlands, Greece, etc., with rapid growth in overseas revenue and increasingly perfect global layout.

Currently, the pace of mid to late stage project financing in the primary market is generally slowing down, and Tupai Medical has received investment from top tier star institutions in this round, fully reflecting its outstanding technical strength and outstanding market performance.

For such a high growth industry leader——
Xu Chuansheng, founding managing partner of Jingwei Venture Capital, stated that China has the highest number of patients with common ophthalmic diseases. With the popularization of electronic products and an aging population, the clinical demand in the field of ophthalmology continues to rise, driving the rapid development of the market for accurate diagnosis and treatment in ophthalmology. In just a few years since its establishment, Tupai Medical has broken the import monopoly through bottom-up independent innovation, and has already taken the lead in multiple product lines domestically and made breakthroughs overseas. We look forward to the company becoming a globally competitive high-end equipment platform for ophthalmic diagnosis and treatment.

Yu Jianlin, Deputy General Manager of Gaotejia Investment Group, said: We are pleased to participate in this round of financing for Tupai Medical and firmly believe in Tupai's leading advantages and comprehensive strength in the field of ophthalmic equipment. Ophthalmic medical equipment is a billion dollar race track that has long been monopolized by imports, and there is great room for domestic substitution. As a leading enterprise in the field of ophthalmic medical equipment, Tupai has launched the world's fastest 400000 scan OCT in ophthalmic OCT, truly achieving global leadership in product performance. Its OCT market share has surpassed imports to become the first in China. Tupai has the strongest comprehensive R&D team in the industry, and has achieved the layout of four diagnostic products including OCT, ophthalmic surgical microscope, ultra wide angle fundus camera, and optical biometric instrument. The product performance fully benchmarks and even partially surpasses imported products, continuously fulfilling the R&D milestone. As a professional investment institution focused on the healthcare industry, Gaotejia will firmly support the development of Tupai Medical. We look forward to the future of Tupai's full range of products benefiting ophthalmic patients worldwide, meeting their unmet clinical needs, and becoming a globally renowned brand in the field of ophthalmic equipment.